Deprescribing Inappropriate Proton Pump Inhibitors
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Bern
About this trial
The DROPIT Trial is an interventional, open-labelled, cluster-randomized controlled trial conducted in the Swiss primary care setting. It aims to evaluate an intervention to guide the deprescribing of inappropriate proton-pump inhibitors (PPIs). Therefore, the trial investigates whether the study intervention leads to the deprescribing of inappropriate PPI prescription while ensuring noninferiority safety, in comparison to usual care. Additionally, the trail aims to investigate the intervention's impact on other clinical aspects, as well as addressing features of the implementation of the intervention and its cost-effectiveness.
Eligibility criteria
Qualifiers
Patient of a participating GP.
Age: minimum 18 years old.
Daily PPI intake for minimum 8 weeks.
minimum 40mg/day pantoprazole;
Disqualifiers
Limited life expectancy according to GP judgement (patients with terminal disease and a life expectancy of less than 12 months.
Unable to provide informed consent.
History of bleeding ulcer.
Peptic ulcer due to cause other than NSAID or H. Pylori.
Trial design
Treatments tested in this trial
- Proton Pump Inhibitor deprescribing tool
Treatment groups
400 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Bern
Lead sponsor
Swiss National Science Foundation
Collaborator
University of Zurich
Collaborator
University of Basel
Collaborator
Insel Gruppe AG, University Hospital Bern
Collaborator
Patientenstelle Zürich
Collaborator
Patientenstelle Basel
Collaborator
Centre Hospitalier Universitaire Vaudois
Collaborator
Source ClinicalTrials.gov